Merck's Ebola Vaccine Will Get US FDA Decision Before March Review Deadline

Staffer says agency will make a licensure decision "well ahead" of the March action date; 230,000 have received the vaccine under compassionate use.

Fake ebola vaccine vial with syringe and stethoscope at the background - Image
Merck's Ebola Vaccine Application Is Getting Speedy FDA Review

The US Food and Drug Administration plans to complete review of Merck & Co. Inc.'s Ebola vaccine application before its March 14 user fee date.

Merck began a rolling submission of the biologics license application for the vaccine, V920 (rVSV∆G-ZEBOV-GP), in October 2018. The FDA...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Vaccines

More from Pink Sheet